IP Library Granted Patent US 12,653,570
Granted Patent B2
US 12,653,570 · App. 17/946,492 · Granted Jun 16, 2026

Atraumatically formed tissue compositions, devices and methods of preparation and treatment

Inventors: Thomas Andrew Davenport (Syosset, NY); Paul Mulhauser (New York, NY); Gregory C. Guinan (Brooklyn, NY)
Assignee: TISSUEMILL TECHNOLOGIES LLC
A61B17/322A61L27/362A61L27/3695C12M45/02C12M45/04C12N5/0629A61B2017/3225
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,570
App. No.
17/946,492
Granted
Jun 16, 2026
Kind
B2
Abstract

A process and system provides for atraumatic preparation of morselized Tissue Particles (TP)s, such as Full Thickness Skin Graft Particles (FTSGPs), cartilage particles and other organ tissue particles, in a liquid medium. The resultant tissue product may be a suspension of Tissue Particles in an aqueous solution and containing highly viable cells and may be rapidly prepared at bedside or in the operating room and conveniently delivered to a patient through a syringe or similar applicator. The morselized Tissues Particles may be used for surgical applications including wound healing, cosmetic surgery, and orthopedic cartilage repairs.

Claims (47)

1 . Tissue particles, harvested from a full thickness skin graft and randomly morselized repeatedly to a random size and shape in a continuous circulating stream of a solution and full thickness skin particles, while maintaining a cell viability of at least 60%, said particles having an average size as measured across a largest dimension selected from the group consisting of: about 0.35 mm to 1.25 mm, about 0.5 mm to about 1.00 mm, about 0.5 mm to about 0.75 mm, about 0.25 mm to about 0.75 mm, and about 0.50 mm.

2 . The morselized tissue particles of claim 1 , wherein the viability is at least 85%.

3 . The morselized tissue particles of claim 1 , wherein the viability is selected from the group consisting of: at least 90%, at least 92%, at least 94%, at least 96%, at least 97%, at least 98%, at least 99%, and 87-98%.

4 . The morselized tissue particles of claim 1 , wherein an average size as measured across a largest dimension is about 0.25 mm to 0.75 mm, and wherein the viability is at least 90%.

5 . The morselized tissue particles of claim 1 , wherein an average size as measured across a largest dimension is about 0.50 mm.

6 . A composition comprising the morselized tissue particles of claim 1 , wherein the composition is in a form selected from the group consisting of a liquid, suspension, dispersion, cream, fluid, emulsion, paste, spray, and injectable.

7 . The composition of claim 6 , further comprising at least one selected from the group consisting of a liquid medium, fibrin glue, autologous platelet rich plasma, growth factors, binders, saline, buffer solution, and cell nurturing/preservation solution.

8 . The composition of claim 7 , wherein the liquid medium is a hydrophilic medium, an oleophilic medium, or an emulsion of hydrophilic and oleophilic mediums.

9 . The composition of claim 6 , wherein the composition is in the form of a suspension, further wherein the suspension is heterogeneous.

10 . The composition of claim 6 , wherein the composition is in the form of a suspension, further wherein the suspension is homogenous.

11 . A surgical procedure comprising:

harvesting the tissue particles of claim 1 ;

processing the harvested tissue for less than 1 hour to prepare morselized tissue particles, wherein the morselized tissue particles have an average size as measured across a largest dimension of about 0.25 mm to 0.75 mm and a viability of at least 85%; and

implanting the morselized tissue particles in a joint of the patient.

12 . Morselized tissue particles, having an average size as measured across a largest dimension of about 0.20 mm to 1.50 mm, and a viability of at least 60%,

wherein the morselized tissue particles are formed using a device for processing organ tissue comprising:

a pair of cutting devices supported in juxtaposition in a container, wherein at least one of the cutting devices is moveable with respect the other cutting device to slice tissue between thereof;

wherein at least one of the cutting devices is fixed with respect the moveable cutting device; and

wherein an agitation device causes a vortex propulsion movement of fluid and tissue through the space between juxtaposed cutting devices.

13 . The morselized tissue particles of claim 12 , wherein the viability is at least 70%.

14 . The morselized tissue particles of claim 12 , wherein the viability is at least 85%.

15 . The morselized tissue particles of claim 12 , wherein the morselized tissue particles are morselized cartilage tissue particles.

16 . The morselized cartilage tissue particles of claim 15 , wherein the viability is at least 85%.

17 . The morselized cartilage tissue particles of claim 15 , wherein the viability is at least 92%.

18 . The morselized cartilage tissue particles of claim 15 , wherein the viability is at least 96%.

19 . The morselized cartilage tissue particles of claim 15 , wherein the viability is 87-98%.

20 . The morselized cartilage tissue particles of claim 15 , having an average size as measured across a largest dimension of about 0.50 mm and a viability of at least 90%.

21 . A composition comprising the morselized cartilage tissue particles of claim 15 , wherein the composition is in a form selected from the group consisting of a liquid, suspension, dispersion, cream, fluid, emulsion, paste, spray, and injectable.

22 . The composition of claim 21 , wherein the morselized cartilage tissue particles have an average size as measured across a largest dimension of about 0.50 mm.

23 . The composition of claim 21 , further comprising at least one selected from the group consisting of a liquid medium, fibrin glue, autologous platelet rich plasma, growth factors, binders, saline, buffer solution, and cell nurturing/preservation solution.

24 . A method of repairing cartilage or treating a cartilage defect in a patient in need thereof, comprising administering the composition of claim 21 to the patient.

25 . The method of claim 24 , wherein the morselized cartilage tissue particles have an average size as measured across a largest dimension of about 0.50 mm.

26 . The method of claim 25 , wherein the composition is administered to the patient via syringe or spatula.

27 . The method of claim 24 , wherein the composition is administered to a joint of the patient.

28 . The method of claim 24 , wherein the morselized cartilage tissue particles is morselized articular cartilage tissue particles.

29 . The morselized cartilage tissue particles of claim 15 , wherein the source of the cartilage tissue is non-articular cartilage, articular cartilage, or a combination thereof.

30 . A cartilage graft, comprising the morselized cartilage tissue particles of claim 15 .

31 . A surgical procedure comprising:

harvesting the tissue particles of claim 12 ;

processing the harvested tissue for less than 1 hour to prepare morselized tissue particles, wherein the morselized tissue particles have an average size as measured across a largest dimension of about 0.25 mm to 0.75 mm and a viability of at least 85%; and

implanting the morselized tissue particles in a joint of the patient.

32 . The surgical procedure of claim 31 , wherein:

the at least one tissue portion is at least one cartilage tissue portion,

the harvested tissue is harvested cartilage, and

the morselized tissue particles are morselized cartilage tissue particles.

33 . The surgical procedure of claim 31 , wherein the harvested cartilage is harvested from the patient's non-articular cartilage or articular cartilage.

34 . Viable tissue particles for treating a patient in need thereof, said tissue particles being harvested from a full thickness skin graft and randomly repeatedly morselized to a size and shape in a continuous circulating stream of a solution and full thickness skin particles, said continuous stream generated by an agitation device which produces a vortex propulsion between juxtaposed cutting devices, said particles having an average size as measured across a largest dimension selected from the group consisting of: about 0.35 mm to 1.25 mm, about 0.5 mm to about 1.00 mm, about 0.5 mm to about 0.75 mm, about 0.25 mm to about 0.75 mm, and about 0.50 mm.

Continuity (5)
Continuation 17236130 · Apr 21, 2021
Continuation 16584755 · Sep 26, 2019
Provisional Application 62844232 · May 7, 2019
Provisional Application 62843724 · May 6, 2019
Related Publication 20230018416A1 · Jan 19, 2023
References Cited (113)
US 2985389A · Willems · 1961 [cited by applicant]
US 3666187A · Norris · 1972 [cited by applicant]
US 4145008A · Wolford · 1979 [cited by applicant]
US 4681571A · Nehring · 1987 [cited by applicant]
US 5731199A · Roggero · 1998 [cited by applicant]
US 6824087B2 · McPherson et al. · 2004 [cited by applicant]
US 7270284B2 · Liao et al. · 2007 [cited by applicant]
US 7431230B2 · McPherson et al. · 2008 [cited by applicant]
US 7794449B2 · Shippert · 2010 [cited by applicant]
US 7980500B2 · Jenni et al. · 2011 [cited by applicant]
US 8109961B2 · Deshmukh · 2012 [cited by applicant]
US 8163549B2 · Yao et al. · 2012 [cited by applicant]
US 8286899B2 · Schowalter et al. · 2012 [cited by applicant]
US 8491497B2 · Houser et al. · 2013 [cited by applicant]
US 9296984B2 · Cimino et al. · 2016 [cited by applicant]
US 9909095B2 · Cimino et al. · 2018 [cited by applicant]
US 9987473B2 · Knowlton · 2018 [cited by applicant]
US 10076354B2 · Knowlton · 2018 [cited by applicant]
US 10080581B2 · Knowlton · 2018 [cited by applicant]
US 10125345B2 · Nash et al. · 2018 [cited by applicant]
US 10219827B2 · Knowlton · 2019 [cited by applicant]
US 10314640B2 · Knowlton · 2019 [cited by applicant]
US 10321948B2 · Knowlton · 2019 [cited by applicant]
US 10335190B2 · Knowlton · 2019 [cited by applicant]
US 10335191B2 · Knowlton · 2019 [cited by applicant]
US 10336980B2 · Cimino et al. · 2019 [cited by applicant]
US 10342574B2 · Knowlton · 2019 [cited by applicant]
US 10368904B2 · Knowlton · 2019 [cited by applicant]
US 10485575B2 · Knowlton · 2019 [cited by applicant]
US 10485606B2 · Knowlton · 2019 [cited by applicant]
US 10517635B2 · Knowlton · 2019 [cited by applicant]
US 10661063B2 · Knowlton · 2020 [cited by applicant]
US 10695546B2 · Knowlton · 2020 [cited by applicant]
US 10702684B2 · Knowlton · 2020 [cited by applicant]
US 10716924B2 · Knowlton · 2020 [cited by applicant]
US 10736653B2 · Knowlton · 2020 [cited by applicant]
US 20050139704A1 · Liao et al. · 2005 [cited by applicant]
US 20060111778A1 · Michalow · 2006 [cited by applicant]
US 20070148756A1 · Bullen · 2007 [cited by examiner]
US 20080089870A1 · Ghosh et al. · 2008 [cited by applicant]
US 20080153157A1 · Yao et al. · 2008 [cited by examiner]
US 20100003300A1 · Markland · 2010 [cited by examiner]
US 20100015202A1 · Semler et al. · 2010 [cited by applicant]
US 20100152750A1 · Memar · 2010 [cited by applicant]
US 20110282238A1 · Houser et al. · 2011 [cited by applicant]
US 20130295673A1 · Taghizadeh et al. · 2013 [cited by applicant]
US 20130338792A1 · Schmieding · 2013 [cited by examiner]
US 20140134212A1 · Shi · 2014 [cited by examiner]
US 20160024450A1 · Quick et al. · 2016 [cited by applicant]
US 20160317170A1 · Knowlton · 2016 [cited by applicant]
US 20160374704A1 · Eriksson et al. · 2016 [cited by applicant]
US 20170224874A1 · Maki et al. · 2017 [cited by applicant]
US 20170296214A1 · Knowlton · 2017 [cited by applicant]
US 20180000504A1 · Knowlton · 2018 [cited by applicant]
US 20180057787A1 · Friedman et al. · 2018 [cited by applicant]
US 20180236457A1 · Graziano et al. · 2018 [cited by applicant]
US 20180250027A1 · Knowlton · 2018 [cited by applicant]
US 20180250502A1 · Knowlton · 2018 [cited by applicant]
US 20180344340A1 · Knowlton · 2018 [cited by applicant]
US 20180344343A1 · Knowlton · 2018 [cited by applicant]
US 20180344344A1 · Knowlton · 2018 [cited by applicant]
US 20180344345A1 · Knowlton · 2018 [cited by applicant]
US 20180353202A1 · Knowlton · 2018 [cited by applicant]
US 20190002821A1 · Raviv · 2019 [cited by applicant]
US 20190054281A1 · Knowlton · 2019 [cited by applicant]
US 20190126020A1 · Knowlton · 2019 [cited by applicant]
US 20190134365A1 · Knowlton · 2019 [cited by applicant]
US 20190254693A1 · Knowlton · 2019 [cited by applicant]
US 20190307480A1 · Knowlton · 2019 [cited by applicant]
US 20220305174A1 · Awad et al. · 2022 [cited by applicant]
AU 2002229615B2 · 2006 [cited by applicant]
CN 2381279Y · 2000 [cited by applicant]
CN 1816280B · 2012 [cited by applicant]
CN 204281757U · 2015 [cited by applicant]
CN 104498350B · 2016 [cited by applicant]
CN 106244418A · 2016 [cited by applicant]
CN 106244437A · 2016 [cited by applicant]
CN 104887292B · 2017 [cited by applicant]
CN 108486043A · 2018 [cited by applicant]
CN 106085819B · 2019 [cited by applicant]
CN 106281991B · 2019 [cited by applicant]
CN 109790504A · 2019 [cited by applicant]
CN 105189729B · 2020 [cited by applicant]
EP 1161208A1 · 2001 [cited by applicant]
EP 1664276B1 · 2013 [cited by applicant]
EP 3378445A1 · 2018 [cited by applicant]
EP 3409369A1 · 2018 [cited by applicant]
EP 2945564B1 · 2019 [cited by applicant]
JP 2010178695A · 2010 [cited by applicant]
KR 101129419B1 · 2012 [cited by applicant]
WO 2012001607A1 · 2012 [cited by applicant]
WO 2015161057A1 · 2015 [cited by applicant]
WO 2015163010A1 · 2015 [cited by applicant]
WO 2018189431A1 · 2018 [cited by applicant]
WO 2019012231A1 · 2019 [cited by applicant]
WO 2019018002A1 · 2019 [cited by applicant]
WO 2025240760A1 · 2025 [cited by applicant]
Reveille Cartilage Processor Handling Technique—13-10-30 Rev A, Exactech, 2016 available at: https://www.exac.com/product/reveille-handling-technique, 2 pages. [cited by applicant]
Reveille® Cartilage Processor, A cost-effective option for single stage surgery with autologous cartilage, Exactech, Mar. 18, 2020, available at: https://www.exac.com/biologics/reveille/, 3 pages. [cited by applicant]
Resource Library, Exactech, Mar. 18, 2020, available at: https://www.exac.com/resource-library/?fwp_brand_categories_dropdown=reveille-cartilage-processor, 1 page. [cited by applicant]
Biologics Main Brochure—713-00-20 Rev C, Exactech, Mar. 18, 2020, available at: https://www.exac.com/product/biologics-main-brochure, 9 pages. [cited by applicant]
PCT Invitation to Pay Additional Fees with Partial International Search, Application No. PCT/US2020/031286, Jul. 31, 2020, 13 pp. [cited by applicant]
Written Opinion, PCT Application No. 2021/027387, dated Jul. 9, 2021, 9 pages. [cited by applicant]
International Search Report, PCT Application No. 2021/027387, dated Jul. 9, 2021, 6 pages. [cited by applicant]
International Search Report, PCT Application No. 2020/031286, dated Sep. 23, 2020, 7 pages. [cited by applicant]
Written Opinion, PCT Application No. 2020/031286, dated Sep. 23, 2020, 10 pages. [cited by applicant]
Canadian Examination Report, CA Application No. 3,138,539, dated Jan. 18, 2022, 3 pages. [cited by applicant]
International Preliminary Report on Patentability, PCT Application No. 2020/031286, dated Nov. 18, 2021, 11 pages. [cited by applicant]
Intellectual Property Office of Singapore Written Opinion, Singapore Application No. 11202112159P, dated Sep. 19, 2022, 5 pages. [cited by applicant]
International Preliminary Report on Patentability, PCT Application No. 2021/027387, dated Nov. 17, 2022, 10 pages. [cited by applicant]
Office Action and Search Report in European Patent Application No. 20727112.3, mailed on Dec. 8, 2023. [cited by applicant]
Written Opinion, PCT Application No. PCT/US2025/029594, dated Aug. 7, 2025, 5 pages. [cited by applicant]
International Search Report, PCT Application No. PCT/US2025/029594, dated Aug. 7, 2025, 9 pages. [cited by applicant]